13F filer · CIK 1615982
Venrock Adviser, LLC
NEW YORK, NY · filing since Q1 2020 · last filing Aug 14, 2026
Reported value
$3.3B
+$618.9M vs prior
Positions
33
New / sold out
4 / 4
Added / reduced
5 / 5
Turnover
3.3%
buys $97.7M · sells $368.9M
Top-10 weight
80.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | ERASCA INC | +1,509,000 | +9.2% | +$27.6M |
| New | ACHIEVE LIFE SCIENCE INC | +2,751,032 | – | +$18.0M |
| New | PARABILIS MEDICINES INC | +625,000 | – | +$17.1M |
| Added | RELMADA THERAPEUTICS INC | +2,000,925 | +41.3% | +$13.8M |
| Added | X4 PHARMACEUTICALS INC | +1,603,728 | +485.2% | +$7.5M |
| Added | SAVARA INC | +1,005,568 | +7.3% | +$6.2M |
| Added | ARTIVA BIOTHERAPEUTICS INC | +434,027 | +27.0% | +$4.2M |
| New | RESEARCH ALLIANCE CORP III | +300,000 | – | +$3.2M |
| New | INMED PHARMACEUTICALS INC | +32,685 | – | +$50.7K |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | KALVISTA PHARMACEUTICALS INC | -6,474,485 | -100.0% | $-130.3M |
| Reduced | SPYRE THERAPEUTICS INC | -700,000 | -19.0% | $-62.1M |
| Reduced | ENLIVEN THERAPEUTICS INC | -1,200,000 | -69.5% | $-60.9M |
| Sold out | ENGENE HOLDINGS INC | -4,771,414 | -100.0% | $-32.5M |
| Sold out | TENAX THERAPEUTICS INC | -1,675,262 | -100.0% | $-26.8M |
| Reduced | CYTOMX THERAPEUTICS INC | -5,000,000 | -50.1% | $-18.8M |
| Reduced | COGENT BIOSCIENCES INC | -357,834 | -17.9% | $-13.8M |
| Sold out | SEPTERNA INC | -506,056 | -100.0% | $-12.2M |
| Reduced | VIRIDIAN THERAPEUTICS INC | -624,792 | -16.1% | $-11.5M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | APOGEE THERAPEUTICS INCCOM | 8,493,321 | $1.1B | 34.18% |
| 2 | ORUKA THERAPEUTICS INCCOM | 4,148,428 | $394.8M | 11.97% |
| 3 | ERASCA INCCOM | 17,891,812 | $327.8M | 9.94% |
| 4 | SPYRE THERAPEUTICS INCCOM NEW | 2,985,448 | $265.0M | 8.04% |
| 5 | DIANTHUS THERAPEUTICS INCCOM | 1,180,000 | $115.0M | 3.49% |
| 6 | OCULAR THERAPEUTIX INCCOM | 10,346,926 | $101.6M | 3.08% |
| 7 | DAMORA THERAPEUTICS INCCOM NEW | 3,603,595 | $93.7M | 2.84% |
| 8 | SAVARA INCCOM | 14,745,943 | $90.8M | 2.75% |
| 9 | JADE BIOSCIENCES INCCOM NEW | 3,220,364 | $71.6M | 2.17% |
| 10 | COGENT BIOSCIENCES INCCOM | 1,642,166 | $63.6M | 1.93% |
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.